- Home
- TARS vs DFIN Comparison
TARS vs DFIN Comparison
Compare TARS & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- DFIN
- Stock Information
- Founded
- TARS 2016
- DFIN 1983
- Country
- TARS United States
- DFIN United States
- Employees
- TARS N/A
- DFIN N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- DFIN Other Consumer Services
- Sector
- TARS Health Care
- DFIN Consumer Discretionary
- Exchange
- TARS Nasdaq
- DFIN Nasdaq
- Market Cap
- TARS 1.8B
- DFIN 1.9B
- IPO Year
- TARS 2020
- DFIN N/A
- Fundamental
- Price
- TARS $53.26
- DFIN $62.60
- Analyst Decision
- TARS Strong Buy
- DFIN Strong Buy
- Analyst Count
- TARS 5
- DFIN 3
- Target Price
- TARS $54.20
- DFIN $76.33
- AVG Volume (30 Days)
- TARS 469.2K
- DFIN 159.6K
- Earning Date
- TARS 11-13-2024
- DFIN 10-31-2024
- Dividend Yield
- TARS N/A
- DFIN N/A
- EPS Growth
- TARS N/A
- DFIN 18.18
- EPS
- TARS N/A
- DFIN 3.18
- Revenue
- TARS $129,621,000.00
- DFIN $802,100,000.00
- Revenue This Year
- TARS $895.24
- DFIN $1.75
- Revenue Next Year
- TARS $73.78
- DFIN $4.27
- P/E Ratio
- TARS N/A
- DFIN $19.68
- Revenue Growth
- TARS 801.96
- DFIN 1.74
- 52 Week Low
- TARS $18.84
- DFIN $56.02
- 52 Week High
- TARS $54.44
- DFIN $71.01
- Technical
- Relative Strength Index (RSI)
- TARS 64.67
- DFIN 56.82
- Support Level
- TARS $48.45
- DFIN $60.52
- Resistance Level
- TARS $53.85
- DFIN $63.62
- Average True Range (ATR)
- TARS 2.40
- DFIN 1.20
- MACD
- TARS -0.14
- DFIN 0.38
- Stochastic Oscillator
- TARS 80.30
- DFIN 76.16
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a global risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( US), Europe, Asia, Canada, and others, of which the US accounts for the vast majority of its total revenue.